SCHEMBL561459

SCHEMBL561459

CC(C)(NC(=O)O)C(=O)NCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 13/20 0.68
RAD52 P43351 3/20 0.67
KIF11 P52732 1/20 0.66
LMNA P02545 6/20 0.65
MAPT P10636 6/20 0.65
SMN1; SMN2 Q16637 5/20 0.65
CYP3A4 P08684 4/20 0.65
MAPK1 P28482 4/20 0.65
TP53 P04637 3/20 0.65
ALDH1A1 P00352 2/20 0.65
CYP1A2 P05177 2/20 0.65
ABCB1 P08183 2/20 0.65
HTR1A P08908 2/20 0.65
ADRA2A P08913 2/20 0.65
ADORA3 P0DMS8 2/20 0.65
CYP2D6 P10635 2/20 0.65
CHRM1 P11229 2/20 0.65
DRD2 P14416 2/20 0.65
ADRA2B P18089 2/20 0.65
ADRA2C P18825 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL560413 0.91 KIF11 (0.71) FPR2RAD52KIF11LMNAMAPT
SCHEMBL560511 0.90 KIF11 (0.70) FPR2RAD52KIF11LMNAMAPT
SCHEMBL10168899 0.87 KIF11 (0.73) FPR2RAD52KIF11LMNAMAPT
SCHEMBL560221 0.85 KIF11 (0.68) FPR2RAD52KIF11LMNAMAPT
SCHEMBL10168902 0.84 KIF11 (0.70) FPR2RAD52KIF11LMNAMAPT
SCHEMBL10168897 0.84 FPR2 (0.70) FPR2RAD52KIF11LMNAMAPT
SCHEMBL560237 0.83 FPR2 (0.67) FPR2RAD52KIF11LMNAMAPT
SCHEMBL10168895 0.83 KIF11 (0.68) FPR2RAD52KIF11LMNAMAPT
Trifluoperazine SCHEMBL27892292 0.82 RAD52 (0.89) FPR2RAD52KIF11LMNAMAPT
SCHEMBL10168440 0.82 FPR2 (0.68) FPR2RAD52KIF11LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035161-A1 Novel Compositions and Methods of Treating Diseases Using the Same CORRIDOR PHARMACEUTICALS, INC. 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035161-A1 Novel Compositions and Methods of Treating Diseases Using the Same NFATC1, BAX, BCL2 FPR2 153/4885RAD52 3198/4885KIF11 3636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.